Three medicines used to treat children who have severe asthma attacks will be compared in a national trial.
Asthma is the most common long-term condition among children and young people.
EVITA will shed light on which of the three treatments: aminophylline, magnesium sulfate or salbutamol, is most effective. This will help to inform clinical guidelines in the future.
Who’s leading it
The EVITA trial has been awarded over £2.3 million from the National Institute for Health and Care Research (NIHR). Southampton’s Professor Graham Roberts and Dr Katrina Cathie will lead the trial, together with Professor Damian Roland in Leicester.
More information can be found at: www.evita.org.uk
At a glance
Trial
EVITA
Funder
NIHR, over £2.3 million
Compares
Aminophylline, magnesium sulfate, salbutamol
Leads
Prof Graham Roberts, Dr Katrina Cathie, Prof Damian Roland